

Amgen Quick Facts:

Headquarters

Thousand Oaks, California

Staff

Approximately 24,000 worldwide
Approximately 680 in The Netherlands

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2020 Financial Highlights

Total revenue: \$25.4 billion
Product sales: \$24.2 billion
R&D expense: \$4.1 billion

Address/Phone

Amgen B.V.
Minervum 7061
4817 ZK BREDA
Phone: +31 (0)76 5732500

PRODUCTS

AMGEVITA™ (adalimumab)
Aranesp® (darbepoetin alfa)
BLINCYTO® (blinatumomab)
KANJINTI™ (trastuzumab)
IMLYGIC® (talimogene laherparepvec)
KANJINTI® (trastuzumab-anns)
Kyprolis® (carfilzomib)
Mimpara® (cinacalcet)
MVASI™ (bevacizumab)
Neulasta® (pegfilgrastim)
Neupogen® (filgrastim)
Nplate® (romiplostim)
Otezla® (apremilast)
Parsabiv™ (etelcalcetide)
Prolia® (denosumab)
Repatha® (evolocumab)
Vectibix® (panitumumab)
XGEVA® (denosumab)

For information: www.amgen.nl

About Amgen

Our Mission: To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but will also help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on the following therapeutic areas: oncology, nephrology, bone health, cardiovascular disease and inflammatory diseases. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

THE AMGEN FOUNDATION

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated nearly \$325 million in grants to local, regional and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, LabXchange, Amgen Biotech Experience and Amgen Teach. For more information, visit www.AmgenInspires.com

AMGEN IN THE NETHERLANDS

Amgen Europe B.V. located in Breda since 1997, is responsible for distribution throughout Europe, Africa, the Middle East and a number of countries in other parts of the world. In Breda, our medicines are packed, labeled, combined with a country specific patient information leaflet and distributed. The marketing, sales and R&D organization ensuring the availability of our products in the Netherlands, Amgen B.V., is also located in Breda. In Breda, approximately 680 employees work every day to serve every patient, every time by producing, selling and distributing our medicines and supporting clinical research on new innovations.

REACHING PATIENTS WORLDWIDE

Amgen medicines help patients worldwide. We have with facilities or subsidiaries in the following locations:

Europe

Austria
Belgium
Bulgaria
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg

Netherlands

Norway
Poland
Portugal
Romania
Russia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
United Kingdom

North America

Canada
Puerto Rico
Mexico
United States

South America

Argentina
Brazil
Colombia

Africa

Algeria
Egypt
Morocco
South Africa

Asia

China
Hong Kong
India
Israel
Japan
Jordan
Korea

Lebanon

Saudi Arabia
Singapore
Taiwan
Thailand
United Arab Emirates

Oceania

Australia
New Zealand

